Olorinab

A Phase 2, multi-center, randomized, double-blind, placebo-controlled, 12-week study to evaluate the efficacy and safety of olorinab in IBS patients experiencing abdominal pain

COMING SOON

Patients may be able to take part in the clinical program if they*:

  • Are 18-70 years of age
  • Have been diagnosed with IBS with constipation or diarrhea (IBS-C or IBS-D)
  • Experience abdominal pain due to IBS
*Other eligibility criteria apply

For more information please visit www.MyIBSPainStudy.com